Caris Life Sciences, Inc.’s Lock-Up Period To Expire on December 15th (NASDAQ:CAI)

Caris Life Sciences’ (NASDAQ:CAI) lock-up period is set to end on Monday, December 15th. Caris Life Sciences had issued 23,529,412 shares in its IPO on June 18th. The total size of the offering was $494,117,652 based on an initial share price of $21.00. After the end of Caris Life Sciences’ lock-up period, restrictions preventing major shareholders and company insiders from selling shares in the company will be lifted.

Wall Street Analysts Forecast Growth

Several brokerages have weighed in on CAI. Wall Street Zen cut Caris Life Sciences from a “buy” rating to a “hold” rating in a report on Saturday. Canaccord Genuity Group raised Caris Life Sciences to a “hold” rating in a research note on Tuesday, December 2nd. Finally, Weiss Ratings began coverage on shares of Caris Life Sciences in a research note on Thursday. They set a “sell (d)” rating on the stock. One research analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, Caris Life Sciences currently has a consensus rating of “Reduce”.

Caris Life Sciences Stock Performance

Shares of CAI stock opened at $28.86 on Monday.

Caris Life Sciences Company Profile

We are a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer. We develop and commercialize innovative solutions to transform healthcare through the use of comprehensive molecular information and artificial intelligence/machine learning algorithms at scale. Our entire portfolio of precision medicine solutions is designed to benefit patients, with an initial focus on oncology, and serves the clinical, academic, and biopharma markets.